BioNTech evokes a return to normal in a year

The general manager of the German company BioNTech, which has developed a vaccine against the new coronavirus with Pfizer, spoke on Sunday of a possible return to normal by next winter.

• Read also: All developments in the COVID-19 pandemic

• Read also: WHO records all-time high for new daily COVID-19 cases

On the BBC, Professor Ugur Sahin considered it “absolutely essential” to have a high vaccination rate before the fall of 2021.

“If everything continues to go well, we will start delivering the vaccine at the end of this year,” he said. “Our goal is to deliver more than 300 million doses of vaccine until April next year, which would allow us to start making an impact” against the virus, which has killed more than 1.3 million in the world.

“The biggest impact will take place until the summer. Summer will help us anyway because the infection rate will drop, ”he continued. “What is absolutely essential is that we have a significant vaccination rate before fall / winter next year.”

“I’m confident that will happen” because many vaccine manufacturers have been asked to increase production, he said, adding, “We could have a normal winter next year.”

According to Pfizer and BioNTech, their vaccine is “90% effective” against COVID-19, according to the large-scale phase 3 trial still underway, the last step before an application for approval. Several other vaccines are also at this stage of research, suggesting the horizon of a return to normal.

Check Also

COVID-19: The hot zone of a partially evacuated geriatric centre

Faced with a major contamination with VIDOC-19 within its “hot zone”, the Maimonides Donald Berman …

Leave a Reply

Your email address will not be published. Required fields are marked *